 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12 |
- | Uzedy (risperidone XR SC suspension) / Teva, MedinCell
Enrollment closed, Enrollment change: Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (clinicaltrials.gov) - May 11, 2020
P3, N=863, Active, not recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Recruiting --> Active, not recruiting | N=596 --> 863
- | Uzedy (risperidone XR SC suspension) / Teva, MedinCell
Trial completion date, Trial primary completion date: Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (clinicaltrials.gov) - Feb 25, 2020
P3, N=596, Recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting --> Active, not recruiting | N=596 --> 863 Trial completion date: Apr 2020 --> Oct 2020 | Trial primary completion date: Jan 2020 --> Aug 2020
- | Uzedy (risperidone XR SC suspension) / Teva, MedinCell
Enrollment open: A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia (clinicaltrials.gov) - Jun 4, 2019
P3, N=300, Recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Trial completion date: Apr 2020 --> Oct 2020 | Trial primary completion date: Jan 2020 --> Aug 2020 Not yet recruiting --> Recruiting
- | Uzedy (risperidone XR SC suspension) / Teva, MedinCell
New P3 trial: A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia (clinicaltrials.gov) - Mar 28, 2019
P3, N=300, Not yet recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
- |||||||||| Uzedy (risperidone XR SC suspension) / Teva, MedinCell
New P3 trial: Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (clinicaltrials.gov) - Apr 18, 2018
P3, N=596, Not yet recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.